Digoxin lipid microbubble and preparation method thereof

Abstract

The invention provides a digoxin lipid microbubble. The digoxin lipid microbubble comprises a lipid bilayer membrane, gas and digoxin-loaded albumin nanoparticles, wherein the gas and the digoxin-loaded albumin nanoparticles are packaged in the lipid bilayer membrane. The digoxin lipid microbubble has relatively high drug loading capacity and encapsulation efficiency, the plasma concentration of a target position can be increased, the action time of drugs at the target position can be prolonged, the degradation of drugs can be reduced, the stability of the drugs can be improved; furthermore, by virtue of the nanoparticles, the selective distribution of the drugs can be promoted, the drugs is beneficially transferred into diseased tissues, the pesticide effect can be increased, and toxic and side effects can be reduced. The invention further discloses a preparation method of the digoxin lipid microbubble. The preparation method is simple in process and easy to industrialize, chemical reactions are not involved in the preparation process, and high-toxicity organic solvents are not utilized, so that the preparation method is high in safety and environmental friendliness.

Description

technical field [0001] The invention relates to digoxin, in particular to digoxin lipid microvesicles and a preparation method thereof. Background technique [0002] Digoxin belongs to cardiac steroids. As early as 2,000 years ago, the ancient Romans used squill (a plant containing cardiac glycosides) extract to treat edema. Later, Europeans used digitalis leaf externally to treat inflammation and abscess. In the 15th century, some people used digitalis preparations to treat heart failure. Digoxin, a typical representative of cardiac glycosides, is directly extracted from the leaves of Digitalis chinensis. It is currently clinically used for various congestive heart failure, atrial fibrillation and arrhythmia. The biggest problem with the clinical use of cardiac glycosides is that the safety range is small, and the effective dose is close to the toxic dose. Once digoxin is poisoned, new arrhythmias, poor appetite or nausea, vomiting, lower abdominal pain, abnormal weaknes...

AI Technical Summary

Problems solved by technology

[0005] Although the research on microbubbles in contrast agents is becoming more and more mature, it is rare to study microbubbles as a new type of drug carrier

Although microbubbles have unique advantages in targeted drug delivery and promotion of drug absorption at the target site, there are many technical difficulties that cannot be overcome at present: for example, as a drug carrier, the drug loading capacity of microbubbles is low, resulting in the delivery to the target site. The concentration of the drug is low, which is not enough for the drug to produce effective pharmacological effects, etc.

Images